You are currently viewing THXE Distillate Information
THXE Distillate Information

THXE is a gold distillate derived from a rare cannabinoid called THCH. It does not contain THCH and is fully converted. The structure contains the base of THCH but with an additional step to retain the potency and characteristics of THCH without testing for it on 3rd party lab tests or customs tests. It is legal in countries that have legalized cannabinoids and carries a strong euphoric sensation. It is psychoactive and should be used in blends only. To get more information, COA, and pictures of THXE.
Please email Jon@bonavoluntate.com or Whatsapp +1 269 331 9905

How to Handle THXE

It is important to handle THXE with care by keeping it out of direct light. The UV rays from sunlight can cause it to decrease in potency slowly. Store THXE in a dry and secure place away from children and pets. We recommend sealing it under nitrogen or argon to help preserve the oil further. THXE has an estimated shelf life of 6 to 12 months. Meaning it is very stable. 

Recommended Uses and Doses

In order to comply with government regulations and safety concerns with higher potency cannabinoids, it is imperative to use THXE in lower concentrations. In vape blends, do not exceed 20-30%. Use with your basic c-noid or psychotropic cannabinoids like H4CBD to give it desired effects. In gummies or edibles, it is important to understand that any cannabinoid that is consumed orally will be converted by the users body to the 11 hydroxy matabolite. This increases the potency and the duration will last longer. Edibles should only contain 2-5mg of this cannabinoid and nothing more. 

Also Read This Article: How to Get Unhigh

Duration and Comparison to THCH

Previous slide
Next slide

Safety

The safety of cannabinoids is very important. Please read this carefully. While there are no long term safety tests of this cannabinoid, we do know how it interacts with the CB1 receptor and how it matabolizes. THXE will operate in a similar mannor to delta 9 thc and delta 9 THCH. Meaning this cannabinoid is a partial agonist against the CB1 receptor. It will bind to the receptor and it is also partially an antagonist meaning it can block other cannabinoids from binding. Read more about the effects of cannabinoids on  CB1 and CB2 receptors here: https://www.cell.com/iscience/fulltext/S2589-0042(20)30488-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004220304880%3Fshowall%3Dtrue 

Dr. John Trant and his team have been able to 3D map various cannabinoids and their positioning with receptors inside the body. This further helps us understand why some are much stronger and why others are not as strong. Digging deeper, John Trant and his team found the following about THCB and THCP: 


Tetrahydrocannabutol (THCB) and Cannabidibutol

One of the essential parameters that can affect the biological activity of THC-like cannabinoids is the length of the C3 alkyl chain. A minimum of three carbons are necessary for receptor binding; activity then increases with increasing number of carbons up to a maximum of eight carbons; for n > 8, activity begins to decrease again (

). Cannazza and colleagues have recently reported two new phytocannabinoids, tetrahydrocannabutol (THCB) and cannabidibutol, both with linear alkyl side chains containing four carbon atoms (

). THCB has thrice the affinity of THC for CB1, with unchanged affinity for CB2 (

). Docking simulations of THCB@ CB1 found binding poses similar to those exhibited by THC and THCV. The main difference between the three ligands was observed in the position of the aliphatic side chain: the butyl chain of THCB does not extend down the TM3-TM5-TM6 tunnel like the pentyl chain of THC (Figure 10C); instead, like the propyl chain of THCV it binds to the small hydrophobic subpocket located near the entrance of the tunnel (Figure 10D). This leads to THCB‘s optimal hydrophobic interaction with F170, F200, and L387, accounting for its exceptional affinity for the CB1 receptor (Figure 10E).

Tetrahydrocannabiphorol (THCP) and Cannabidiphorol (CBDP)

In late 2019, Cannazza and coworkers reported the isolation of two additional phytocannabinoids: tetrahydrocannabiphorol (THCP) and cannabidiphorol, both with C7 linear alkyl side chains (

). THCP has exceptional affinity to both CB1 and CB2, with a Ki of 1.2 and 6.2 nM, respectively, 33-fold the affinity of THC for CB1 and 13-fold higher than THCBTHCP binds to the active conformation of CB1 in an L-shaped pose, approximating that of THC in the presence of CBD (

), with the tetrahydro-6H-benzo[c]chromene ring system occupying the hydrophobic orthosteric pocket. The resorcinyl moiety participates in two edge-to-face π-π interactions with F170 and F268, and the C1 hydroxyl group hydrogen bonds with S383 (Figure 10F). Interestingly, the heptyl chain at C3 extended into a long hydrophobic tunnel formed by L193, V196, Y275, I271, L276, W279, L359, F379, and M363, formed by TM3, TM5, and TM6, along its entire length, maximizing the hydrophobic interactions with the residues along the side of the channel (Figures 10F and 10G). In contrast, the tunnel is only partially occupied by the shorter pentyl chain of THC, helping to account for THCP‘s far higher affinity. This orientation is also different than the pose predicted for the shorter alkyl chain homologs, THCV and THCB, where the chain sits in the side hydrophobic pocket instead. In a murine model, THCP showed promising pharmacological activities associated with CB1 agonists including reduced motility, analgesia, catalepsy, and decreased rectal temperature.

We encourage our readers to dive into this research article and learn more about the diagrams depicting the binding of different cannabinoids with CB1 and CB2 receptors. It will help you understand why each cannabinoid has different strength’s, durations, and effects.

Choose the commodity you wish to order from the drop down list.
Selected Value: 100

About Author

Jon Bona

Jon Bona

Jon Bona has been serving as the Director of Operations at Bona Voluntate since 2021. With a strong commitment to advancing the cannabis industry, Jon specializes in developing and promoting high-quality cannabis-derived products and extracts.

Jon’s career in the cannabis sector began over a decade ago, where he focused on optimizing operations and ensuring sustainable practices. His expertise has been crucial in educating consumers about the benefits of cannabis, and he is dedicated to providing safe, effective, and reliable products.

In addition to his role at Bona Voluntate, Jon is actively engaged in the cannabis community. He regularly contributes articles on the latest research, trends, and practical tips for consumers. His insights are a blend of professional experience and a genuine passion for the industry.

For more information, visit Bona Voluntate and Voluntate Shop.

This Post Has One Comment

Leave a Reply